Back to top
more

Privia Health Group (PRVA)

(Delayed Data from NSDQ)

$18.17 USD

18.17
1,024,868

-0.63 (-3.35%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $18.16 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Privia Health (PRVA) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Privia Health (PRVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Privia Health (PRVA) Misses Q4 Earnings Estimates

Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 3.02%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

OMCL vs. PRVA: Which Stock Should Value Investors Buy Now?

OMCL vs. PRVA: Which Stock Is the Better Value Option?

Compared to Estimates, Privia Health (PRVA) Q3 Earnings: A Look at Key Metrics

The headline numbers for Privia Health (PRVA) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Privia Health (PRVA) Q3 Earnings Miss Estimates

Privia Health (PRVA) delivered earnings and revenue surprises of -16.67% and 1.59%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

GEHC or PRVA: Which Is the Better Value Stock Right Now?

GEHC vs. PRVA: Which Stock Is the Better Value Option?

GEHC or PRVA: Which Is the Better Value Stock Right Now?

GEHC vs. PRVA: Which Stock Is the Better Value Option?

GEHC or PRVA: Which Is the Better Value Stock Right Now?

GEHC vs. PRVA: Which Stock Is the Better Value Option?

Privia Health (PRVA) Q2 Earnings and Revenues Surpass Estimates

Privia Health (PRVA) delivered earnings and revenue surprises of 20% and 5.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

GEHC vs. PRVA: Which Stock Is the Better Value Option?

GEHC vs. PRVA: Which Stock Is the Better Value Option?

Privia Health (PRVA) Surpasses Q1 Earnings and Revenue Estimates

Privia Health (PRVA) delivered earnings and revenue surprises of 100% and 2.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Privia Health (PRVA) Expected to Beat Earnings Estimates: Should You Buy?

Privia Health (PRVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Signify (SGFY): Can Its 5.8% Jump Turn into More Strength?

Signify (SGFY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Are Options Traders Betting on a Big Move in Privia Health Group (PRVA) Stock?

Investors need to pay close attention to Privia Health Group (PRVA) stock based on the movements in the options market lately.

Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Tops Revenue Estimates

Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50% and 11.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Privia Health (PRVA) Reports Q2 Loss, Tops Revenue Estimates

Privia Health (PRVA) delivered earnings and revenue surprises of -400% and 7.53%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) Reports Q2 Loss, Lags Revenue Estimates

Invitae (NVTA) delivered earnings and revenue surprises of 8.11% and 0.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Privia Health (PRVA) to Report a Decline in Earnings: What to Look Out for

Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Change Healthcare (CHNG) Q1 Earnings and Revenues Miss Estimates

Change Healthcare (CHNG) delivered earnings and revenue surprises of -2.56% and 0.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Privia Health (PRVA) Moves 7.4% Higher: Will This Strength Last?

Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Privia Health (PRVA) Surges 8.1%: Is This an Indication of Further Gains?

Privia Health (PRVA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Privia Health (PRVA) Tops Q1 Earnings and Revenue Estimates

Privia Health (PRVA) delivered earnings and revenue surprises of 500% and 5.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Privia Health (PRVA) Q1 Earnings Expected to Decline

Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.